

Habtamu, Esmael; Wondie, Tariku; Tadesse, Zerihun; Atinafu, Bezawit; Gashaw, Bizuayehu; Gebeyehu, Abebaw; Kelly Callahan, E; Macleod, David; Burton, Matthew J; (2019) Posterior lamellar versus bilamellar tarsal rotation surgery for trachomatous trichiasis: Longterm outcomes from a randomised controlled trial. EClinicalMedicine. ISSN 2589-5370 DOI: https://doi.org/10.1016/j.eclinm.2019.10.015

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655109/
DOI: https://doi.org/10.1016/j.eclinm.2019.10.015

## Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/

Research Paper

# Posterior lamellar versus bilamellar tarsal rotation surgery for trachomatous trichiasis: Long-term outcomes from a randomised controlled trial 

Esmael Habtamu ${ }^{\text {a,b,*, Tariku Wondie }}{ }^{\text {b }}$, Zerihun Tadesse ${ }^{\text {b }}$, Bezawit Atinafu ${ }^{\text {b }}$, Bizuayehu Gashaw ${ }^{\text {c }}$, Abebaw Gebeyehu ${ }^{\text {c }}$, E. Kelly Callahan ${ }^{\text {d }}$, David Macleod ${ }^{\mathrm{e}}$, Matthew J. Burton ${ }^{\text {a }}$<br>${ }^{\text {a }}$ International Centre for Eye Health, Department of Clinical Research, London School of Hygiene \& Tropical Medicine, London, UK<br>${ }^{\mathrm{b}}$ The Carter Center, Addis Ababa, Ethiopia<br>${ }^{\text {c }}$ Amhara Regional Health Bureau, Bahirdar, Ethiopia<br>${ }^{\text {d }}$ The Carter Center, Atlanta, USA<br>${ }^{\mathrm{e}}$ Department of Infectious Disease Epidemiology, London School of Hygiene \& Tropical Medicine, London, UK

## A R T I C L E I N F O

## Article history:

Received 9 August 2019
Revised 14 October 2019
Accepted 21 October 2019
Available online xxx

## Keywords:

Trachoma
Trichiasis
Ethiopia
Surgery
Postoperative
Recurrence


#### Abstract

Background: We re-examined the participants of a clinical trial four years after enrolment to identify which of the two most commonly used eyelid surgery procedures to treat the blinding stage of trachoma (trachomatous trichiasis, TT), the posterior Lamellar Tarsal Rotation (PLTR) and Billamelar Tarsal Rotation (BLTR), gives better results in the long-term. Methods: A randomised, controlled, single masked clinical trial was done in Ethiopia. At baseline, adults (aged $>18$ years with upper lid unoperated TT were recruited from a community-based screening. Participants were randomly assigned (1:1), to either BLTR or PLTR surgery, stratified by surgeon. At 4 years an independent assessor masked to allocation examined the trial participants' eyes using the same procedures as for the baseline and earlier follow-ups. The primary outcome was the proportion of individuals who had recurrence (postoperative TT, PTT) at the 4 -year examination, or a history of repeat surgery in the 4 -year period. The intervention effect was estimated by logistic regression, controlled for surgeon as a fixed effect in the model. The trial is registered with the Pan African Clinical Trials Registry (number PACTR201401000743135). Findings: 1000 participants with TT were enrolled, randomly assigned, and treated ( 501 in the BLTR group and 499 in the PLTR group) between Feb 13, 2014, and May 31, 2014. At year 4, 943 ( $94.3 \%$ ) participants were re-examined (471, PLTR; 472, BLTR) and included in the primary outcome analysis. PTT had developed in $169 / 943(17 \cdot 9 \%)$ study eyes, among which $129(76 \cdot 3 \%)$ had minor trichiasis ( $\leq 5$ lashes touching the eye). PTT was significantly more frequent at 4 -year in the BLTR arm (105/472 [22•2\%]) than the PLTR arm (64/471 [13•6\%]), adjusted OR $1 \cdot 82(95 \% \mathrm{CI}, 1 \cdot 29-2 \cdot 56) ; p=0 \cdot 0006$, with $8 \cdot 6 \%(95 \% \mathrm{CI} 3 \cdot 8-13 \cdot 5)$ risk difference. Interpretation: The PLTR surgical procedure had superior long-term outcomes to the BLTR with significantly lower risk of PTT supporting the current WHO guideline that the PLTR should be the procedure of choice for training new surgeons in the programmatic management of TT. © 2019 Published by Elsevier Ltd. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)


## Research in context

Evidence before this study
Our study group conducted and published a systematic review of the management of trachomatous trichiasis searching CENTRAL, Ovid MEDLINE, EMBASE, ISRCTN registry, ClinicalTrials.gov, WHO ICTRP. The only randomised trial which compared variants of the

[^0]Bilamellar Tarsal Rotation (BLTR) and Posterior Lamellar Tarsal Rotation (PLTR) surgical procedures performed by ophthalmologists in a teaching hospital in Ethiopia was conducted on 153 patients in 2002, which found no evidence of a difference in outcome after three months. We conducted a randomised, controlled, single masked clinical trial between February and May 2015 to determine the relative effectiveness of the PLTR and BLTR Ethiopia in larger sample ( 1000 patients) in a programmatic setting in Ethiopia. The 12 -month results showed that the PLTR was superior to BLTR giving a substantially lower trichiasis recurrence rate by one year and fewer intra and immediate post-operative complications. There is no data on the long-term outcome of these two surgical procedures from a head to head comparison trial.

## Added value of this study

The one-year results of our trial led to a shift in international guidance from BLTR being the treatment of choice to treat trachomatous trichiasis to a preference for new trainees to be taught PLTR. However, there was much international interest to see the long-term outcome of the PLTR and BLTR. Our trial participants were examined four years after randomised intervention to assess the long-term outcome of these two procedures and to ascertain whether the superiority of PLTR would be sustained beyond one year. The results showed that the PLTR surgical procedure had still superior long-term outcomes to the BLTR with significantly lower risk of recurrent trichiasis four years after surgery.

## Implications of all the available evidence

The available evidences support the current WHO guideline that the PLTR should be the procedure of choice for training new surgeons in the programmatic management of TT.

## 1. Introduction

Trachomatous Trichiasis (TT), the blinding stage of trachoma, is mainly treated with corrective eyelid surgery [1,2]. Many surgical procedures have been tried for the management of TT [3]. However, the two most commonly used surgical procedures are the Posterior Lamellar Tarsal Rotation (PLTR) and the Bilamellar Tarsal Rotation (BLTR) surgeries [2]. The type of surgical procedure is thought to be one of the major determinants of outcome of TT surgery [4-8]. Poor surgical outcomes pose a major challenge for surgical programmes worldwide. Trichiasis typically recurs in around $20 \%$ of patients within a year, and about $10 \%$ develop eyelid contour abnormality (ECA) [9-12]. Empirical data indicate that poor surgical outcomes deter patients from accepting trichiasis surgery [13], possibly contributing to the recent decline in surgical uptake in some trachoma control programmes [14].

Four years ago, we conducted a randomised, controlled, single masked clinical trial to compare the relative effectiveness of the PLTR and BLTR procedures. One year after surgery we found that the cumulative rate of recurrent trichiasis (here after postoperative trachomatous trichiasis, PTT) was more frequent in the BLTR group than in the PLTR group with a $9.5 \%$ risk difference [9]. Following this, international guidance on the surgical treatment of choice was updated, shifting away from BLTR being the treatment of choice to a preference for new trainees to be taught PLTR [15].

There are about 3 million un-operated cases of TT globally [16], requiring surgery using the safest and most successful procedure. However, there are currently no long-term data directly comparing these two surgical procedures. Some studies have reported that the
rate of PTT may increase from about $20 \%$ at 1 -year to as much as $60 \%$ at 3 years after surgery [4,5,11,12,17-19].

In this long-term follow-up of a randomised controlled surgical trial, we followed and examined trial participants four years after enrolment to investigate the long-term outcomes of BLTR and PLTR surgery, and to ascertain whether the superiority of the PLTR outcome was sustained beyond one year.

## 2. Methods

### 2.1. Study design and participants

The trial methods have been previously described in detail [9,20]. In summary, a randomised, controlled, single masked clinical trial was conducted in Ethiopia between Feb 13, 2014, and April 30, 2015. Adults with TT defined as one or more eyelashes touching the eye or evidence of epilation, identified from a communitybased screening in districts of West Gojam Zone, Amhara Region, Ethiopia were examined for eligibility. People with trichiasis due to other causes, recurrent trichiasis after previous surgery, hypertension, pregnancy, and those under 18 years were excluded. Those eligible and consented to participate following a written informed consent in Amharic were enrolled. This report adhered to standard CONSORT guidelines.

### 2.2. Randomisation and masking

Participants were randomly assigned (1:1) to either PLTR or BLTR surgery. Randomisation was stratified by surgeon and sequences were computer-generated by an independent statistician with random block sizes of 4 or 6 . Allocations were concealed in sequentially numbered, sealed, opaque envelopes. Examiners who were responsible for clinical observations at baseline and followups were masked to allocation. The surgery was performed by six experienced nurse/health officer trichiasis surgeons. These were already trained, certified, and regularly performing PLTR surgery. They were trained rigorously on the BLTR procedure using the WHO trichiasis surgery training manual [2], and were then restandardised on both surgical procedures after six-months of regular practice.

### 2.3. Procedures

Participant eyes were examined (EH) at baseline prior to randomisation using $2.5 \times$ binocular loupes and torch, and graded using the detailed World Health Organisation (WHO) Follicles Papillae Cicatricae (FPC) Grading System [21].. The number, location and type of trichiasis lashes, corneal scarring, and tarsal conjunctival scarring and inflammation were graded and recorded. Presenting distance logMAR (Logarithm of the Minimum Angle of Resolution) visual acuity was measured using PeekAcuity software on a Smartphone in a dark room [22]. Four standardized high-resolution digital photographs of trichiasis, cornea, and tarsal conjunctiva were taken. After the randomisation, during the surgeries, intraoperative and immediate postoperative observations were made to measure incision length, height and regularity by three trained nurses. Number of scissor cuts made to make an adequate dissection medially and laterally. The number, spacing and tension of the mattress sutures were recorded.

Participants were re-examined at 10-days, 6-months, and 12months postoperatively, following the same assessment procedures as per baseline. The only additional elements were assessment for granuloma, level of eyelid correction, and post-operative eyelid contour abnormalities (ECA). ECA were graded according to the PRET trial methodology [23], and grouped for analysis: (1) clinically non-significant ECA, which included mild ECA; and


Fig. 1. Trial Profile.
(2) clinically significant ECA, which included moderate-to-severe ECA.

The four-year follow-up was approved by the Ethiopian National Health Research Ethics Review Committee, the London School of Hygiene \& Tropical Medicine Ethics Committee, Emory University Institutional Review Board, and the Ethiopian Food, Medicine and Healthcare Administration and Controls Authority. The study was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonisation-Good Clinical Practice.

Trial participants were re-contacted and invited to attend a four-year follow-up assessment at a local health facility. Those who were not able to come to the health facilities were examined in their homes. Reasons for loss to follow-up were identified and documented. Written informed consent in Amharic had been obtained at baseline, before the initial enrolment from participants. The participants were re-consented at the four-year follow-up. If a participant was unable to read and write, the information sheet and consent form were read to them and their consent recorded by thumbprint.

Participants were asked about any repeat surgery, epilation in the last 6 -month, and satisfaction with their surgical outcome. They were examined following the same procedure as outlined above. Outcome assessment was conducted by an independent examiner (BA) who was masked to the intervention allocation and who had no prior involvement in randomisation allocation, outcome assessment, and data analysis. The four-year examiner received rigorous training and was standardised with the baseline
and 12-month outcome assessor (EH). They had very strong agreement for the primary outcome ( $k=0.98$ ).

## 3. Outcomes

Prior to the start of the 4 -year follow-up, a single primary end point was prespecified in the approved protocol. The primary end point was postoperative TT at 4 -years analysed as the proportion of individuals who developed one or more lashes touching the eye or clinical evidence of epilation at the 4 -year examination, or a history of repeat surgery in the 4 -year period. The secondary analysis of the primary outcome measure was cumulative PTT defined as the proportion of individuals who had developed PTT by 4 -years, defined as one or more lashes touching the eye or clinical evidence of epilation at all follow-ups (10 day, 6- and 12 -months, and 4 -year), or a history of repeat surgery in the 4 -year period.

Secondary outcome measures included: PTT difference by surgeon and baseline disease severity; under correction; eyelid contour abnormality prevalence and regression at 4 -year, corneal opacity and vision changes; effect of PTT on corneal opacity and vision changes, factors influencing long term outcomes; and patientreported outcomes.

### 3.1. Statistical analysis

Sample size determination was described in the 12 -month results paper [9]. Data were double-entered into Access 13 (Microsoft) and transferred to Stata 14 (StataCorp) for analysis. For

Table 1
Demographic and clinical characteristics of cases seen at 4-year follow-up.

| Characteristic | Treatment groups at baseline |  |  |  | Participants seen at 4-years |  |  |  | 4 -year |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | PLTR <br> n/499 | (\%) | $\begin{aligned} & \text { BLTR } \\ & n / 501 \end{aligned}$ | (\%) | PLTR <br> n/471 | (\%) | $\begin{aligned} & \text { BLTR } \\ & n / 472 \end{aligned}$ | (\%) | PLTR <br> n/471 | (\%) | $\begin{aligned} & \text { BLTR } \\ & \mathrm{n} / 472 \end{aligned}$ | (\%) |
| Gender (female) | 388 | (77•8) | 377 | (75.2) | 366 | (77.7) | 353 | (74*8) | - | - | - | - |
| Age (mean, SD) | 47.2 | $15 \cdot 0$ | $47 \cdot 5$ | (14.9) | $46 \cdot 6$ | (14.4) | $46 \cdot 8$ | (14•4) | - | - | - | - |
| Trichiasis severity |  |  |  |  |  |  |  |  |  |  |  |  |
| No trichiasis | - |  | - |  | - | - | - | - | 407 | (86•4) | 367 | (77-8) |
| Minor (1-5) | 267 | (53.5) | 258 | (51.5) | 252 | (53.5) | 250 | (53.0) | 48 | (10.2) | 81 | (17.2) |
| Major (6-9) | 232 | (46.5) | 243 | (48.5) | 219 | (46.5) | 222 | (47•0) | 5 | $(1 \cdot 1)$ | 12 | (2.5) |
| Repeat surgery* | - | - | - | - | - | - | - | - | 11 | (2.3) | 12 | (2.5) |
| Median (IQR) $\dagger$ |  |  |  |  | 3 | (2-6) | 3 | (2-6) | 1 | (1-2) | 2 | (1-4) |
| Trichiasis lash location |  |  |  |  |  |  |  |  |  |  |  |  |
| No lashes | - |  | - |  | - | - | - | - | 407 | (86•4) | 367 | (77-8) |
| Epilating | 38 | (7-6) | 44 | (8.8) | 38 | (8.1) | 40 | (8.5) | 5 | $(1 \cdot 1)$ | 14 | (3.0) |
| Corneal | 383 | (76.7) | 376 | (75.0) | 359 | (76-2) | 361 | (76.5) | 28 | (5.9) | 46 | (9.7) |
| Medial | 3 | (0.6) | 0 | (0.0) | 3 | (0.6) | 0 | (0.0) | 8 | (1-7) | 8 | (1-7) |
| Lateral | 8 | (1.6) | 5 | (1.0) | 8 | (1.7) | 4 | (0•8) | 4 | (0•8) | 5 | (1•1) |
| Corneal + Peripheral | 67 | (13.4) | 76 | (15.2) | 63 | (13.4) | 67 | (14.2) | 8 | (1.7) | 20 | (4.2) |
| Repeat surgery | - | - | - | - | - | - | - | - | 11 | (2.3) | 11 | (2•5) |
| Trichiasis lash type |  |  |  |  |  |  |  |  |  |  |  |  |
| No lashes | - | - | - | - | - | - | - | - | 407 | (86•4) | 367 | (77-8) |
| Epilating | 38 | (7-6) | 44 | (8.8) | 38 | (8.1) | 40 | (8.5) | 5 | (1-1) | 14 | (3.0) |
| Entropic only | 126 | (25-2) | 117 | (23-3) | 121 | (25.7) | 111 | (23.5) | 19 | (4•0) | 32 | (6•8) |
| Metaplastic only | 224 | (44.9) | 206 | (41•1) | 209 | (44•4) | 195 | $(41 \cdot 3)$ | 24 | $(5 \cdot 1)$ | 35 | (7-4) |
| Misdirected only | 9 | (1•8) | 14 | (2•8) | 9 | (1.9) | 14 | (3.0) | 1 | (0.2) | 2 | (0•4) |
| Mixed | 102 | $(20 \cdot 4)$ | 120 | (23.9) | 94 | $(20 \cdot 0)$ | 112 | (23.7) | 4 | (0.8) | 10 | (2•1) |
| Repeat surgery |  |  |  |  | - | - | - | - | 11 | (2.3) | 12 | (2•5) |
| Tarsal conjunctiva inflammation ${ }^{\text {a }}$ |  |  |  |  |  |  |  |  |  |  |  |  |
| None (PO) | 6 | (1-2) | 9 | (1-8) | 5 | (1-1) | 9 | (1-8) | 9 | (1.9) | 7 | (1-5) |
| Mild (P1) | 117 | (23.4) | 131 | (26•1) | 109 | (23•1) | 121 | (25•6) | 239 | (50•8) | 220 | (46.6) |
| Moderate (P2) | 306 | (61.3) | 297 | (59.3) | 294 | (62.4) | 281 | (59.5) | 208 | (44.3) | 228 | (48.3) |
| Severe (P3) | 70 | (14.0) | 64 | $(12 \cdot 8)$ | 63 | (13.4) | 61 | (12.9) | 14 | (3.0) | 17 | (3•6) |
| Best corrected $\operatorname{logMAR}$ VA in study eye |  |  |  |  | 63 |  |  |  |  |  |  |  |
| -0.1 to 0.3 | 141 | (28.7) | 137 | (27-3) | 138 | (29.3) | 135 | (28.6) | 171 | (36.3) | 157 | (33.3) |
| $0 \cdot 3$ to $0 \cdot 7$ | 190 | (38.1) | 209 | (41.7) | 183 | (38.8) | 200 | (42.4) | 186 | (39.5) | 205 | (43.4) |
| $0 \cdot 7$ to $1 \cdot 1$ | 107 | (21-4) | 103 | (20.6) | 102 | $(21 \cdot 7)$ | 93 | (19.7) | 72 | (15.3) | 76 | (16•1) |
| $1 \cdot 1$ to $2 \cdot 0$ | 18 | (3.6) | 18 | (3-6) | 15 | (3-2) | 18 | (3•8) | 13 | (2•8) | 5 | (1•1) |
| CF/HM/PL | 37 | (7-4) | 27 | (5-4) | 30 | $(6 \cdot 4)$ | 20 | (4•2) | 24 | $(5 \cdot 1)$ | 22 | $(4 \cdot 7)$ |
| NPL | 6 | (1-2) | 7 | (1-4) | 3 | (0•6) | 6 | (1-3) | 3 | $(0 \cdot 6)$ | 5 | $(1 \cdot 1)$ |
| Not taken | - | - | - | - |  | - | - | - | 2 | (0.4) | 2 | (0•4) |
| Corneal opacity ${ }^{\text {b }}$ |  |  |  |  | - |  |  |  |  |  |  |  |
| None (CC0) | 121 | (24-2) | 132 | (26.3) | 114 | (24-2) | 128 | (27•1) | 137 | (29•1) | 129 | (27•6) |
| Peripheral (CC1) | 204 | (40.9) | 201 | (40•1) | 193 | (40.9) | 184 | (38.9) | 57 | (12•1) | 62 | (13.2) |
| Off centre faint (CC2a) | 94 | (18.8) | 94 | (18.7) | 90 | (19.1) | 91 | (19.3) | 92 | (19.6) | 97 | (20.7) |
| Off centre dense (CC2b) | 19 | (3.8) | 11 | (2.2) | 19 | (4•0) | 10 | (2•1) | 6 | (1-3) | 8 | (1-7) |
| Central faint (CC2c) | 48 | (9.6) | 50 | $(10 \cdot 0)$ | 44 | (9.3) | 47 | $(10 \cdot 0)$ | 150 | (31.9) | 147 | (31-4) |
| Central dense (CC2d) | 7 | (1-4) | 7 | (1•4) | 6 | (1.3) | 7 | (1•5) | 23 | (4.5) | 21 | (4.5) |
| Total central dense (CC3) | 4 | $(0 \cdot 8)$ | 6 | (1-2) | 4 | $(0 \cdot 8)$ | 5 | $(1 \cdot 1)$ | 3 | $(0 \cdot 6)$ | 4 | (0•8) |
| Phthisis (CC4) | 2 | (0.4) | 0 | (0•0) | 1 | (0.2) | 0 | (0.0) | 2 | (0.4) | 0 | (0•0) |

* 2 participants had repeat surgery between baseline and 12-month (one from each arm).
${ }^{\text {a }}$ One missing value in the PLTR arm.
${ }^{\mathrm{b}}$ Five missing values (one in the PLTR, four in the BLTR).
participants who had bilateral surgery, the same randomly designated eye used for the 12 -month analysis was used for the 4 year follow-up analysis (i.e. one eye only per participant included in analysis).

A modified intention-to-treat analysis was performed (modified meaning that participants who died during follow-up or were not seen at follow up for another reason were excluded). Otherwise all trial participants were analysed in the groups they were originally randomised and included in the analysis if they were seen at the 4 -year follow-up (for the primary analysis) and at least at one follow-up time point (for the secondary analysis of the primary outcome). The effect of the intervention on primary outcome and binary secondary outcomes (cumulative PTT difference, PTT by baseline disease severity, under correction) was analysed using logistic regression to estimate the odds ratio (OR) and $95 \% \mathrm{CI}$. All comparisons between the two surgical procedures were controlled
for surgeon as a fixed effect in the model, to account for the stratified randomisation. Vision and corneal opacity changes between baseline and 4 -years were categorised as worse, same, better. Effect of the intervention on ordered categorical secondary outcomes (changes in visual acuity and corneal opacity, and patient-reported outcomes) were analysed using ordinal logistic regression. Intervention effects on ECA (categorical variable) prevalence and regression at 4 -year were analysed using multinomial logistic regression to estimate relative risk ratio (RRR) and $95 \% \mathrm{Cl}$. A non-prespecified sign test was used to analyse if ECA regression between 6 - and 12 month, and 12 -month and 4 -year is statistically significant in all study participants. In order to identify potential predictors of PTT at 4 years, first a univariable logistic regression was performed using PTT at 4 years as an outcome and factors with possible association with PTT (covariates) as exposures and was done separately for each intervention arm, before including all covariates

Table 2
Secondary clinical and patient reported outcomes.

| Variables and clinical outcomes | $\begin{aligned} & \text { PLTR } \\ & n / N \end{aligned}$ | (\%) | $\begin{aligned} & \text { BLTR } \\ & n / N \end{aligned}$ | (\%) | OR | (95\% CI) | $P$ value |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Surgeon effect on PTT at 4 years ${ }^{\text {a }}$ |  |  |  |  |  |  |  |
| 1 | 10/85 | (11•8) | 25/89 | (28-1) | $2 \cdot 93$ | (1•31-6.56) | 0.0089 |
| 2 | 10/90 | (11•1) | 18/90 | (20.0) | $2 \cdot 00$ | (0.87-4•61) | $0 \cdot 10$ |
| 3 | 14/79 | (17•7) | 15/78 | (19.2) | $1 \cdot 10$ | (0•49-2•48) | $0 \cdot 81$ |
| 4 | 12/85 | (14.1) | 20/91 | (22•0) | $1 \cdot 71$ | (0.78-3.76) | $0 \cdot 18$ |
| 5 | 6/46 | (13.0) | 10/45 | (22.2) | $1 \cdot 90$ | (0.63-5.77) | $0 \cdot 25$ |
| 6 | 12/86 | (13.9) | 17/79 | (21-5) | $1 \cdot 69$ | (0•75-3•81) | $0 \cdot 20$ |
| PTT by baseline trichiasis severity ${ }^{\text {a }}$ |  |  |  |  |  |  |  |
| Minor TT | 25/252 | (9.9) | 35/250 | (14.0) | $1 \cdot 50$ | (0.87-2•61) | $0 \cdot 15$ |
| Major TT | 39/219 | (17•8) | 70/222 | (31-5) | $2 \cdot 12$ | (1•35-3.33) | 0•0011 |
| PTT by baseline entropion severity ${ }^{\text {a }}$ |  |  |  |  |  |  |  |
| None/Mild | 11/99 | (11•1) | 22/85 | (25.9) | $2 \cdot 87$ | (1•26-6.55) | $0 \cdot 012$ |
| Moderate | 35/296 | (11•8) | 62/316 | (19.6) | $1 \cdot 80$ | (1•15-2•84) | 0.010 |
| Severe | 18/76 | (23.7) | 21/71 | (29•6) | $1 \cdot 37$ | (0.64-2•91) | $0 \cdot 42$ |
| Under correction in any part of the eyelid ${ }^{\text {a }}$ |  |  |  |  |  |  |  |
| No | 396 | (84•4) | 373 | (79.2) | $1 \cdot 44$ | (1•03-2•02) | $0 \cdot 034$ |
| Yes | 73 | (15•6) | 98 | (20•8) |  |  |  |
| Eyelid contour abnormality at 4-yr ${ }^{\text {b }}$ |  |  |  |  |  |  |  |
| None (base outcome) | 420 | (89.2) | 432 | (91-5) | 1 | - | - |
| Clinically None-significant (Mild) | 32 | (6.8) | 17 | (3-6) | $0 \cdot 52$ | (0.28-0.95) | $0 \cdot 033$ |
| Clinically Significant (Moderate and Severe) | 19 | (4•0) | 23 | (4•9) | $1 \cdot 18$ | (0.63-2.21) | $0 \cdot 60$ |
| Satisfaction with effect of surgery on the trichiasis at 4-yr ${ }^{\text {c }}$ |  |  |  |  |  |  |  |
| Satisfied | 438 | (93•0) | 436 | (92•6) | $1 \cdot 06$ | (0•65-1•74) | $0 \cdot 81$ |
| Neither satisfied nor dissatisfied | 8 | (1-7) | 9 | (1-9) |  |  |  |
| Dissatisfied | 25 | (5.3) | 26 | (5-5) |  |  |  |
| Satisfaction with the cosmetic appearance at 4-yr ${ }^{\text {c }}$ |  |  |  |  |  |  |  |
| Satisfied | 453 | (96.2) | 453 | (96.2) | $1 \cdot 00$ | (0.51-1•96) | $0 \cdot 99$ |
| Neither satisfied nor dissatisfied | 6 | (1-3) | 6 | (1•3) |  |  |  |
| Dissatisfied | 12 | (2.5) | 12 | (2.5) |  |  |  |
| Vision changes, baseline to 4-yr ${ }^{\text {c }}$ |  |  |  |  |  |  |  |
| Worse | 146 | (31•1) | 127 | (27•0) | $1 \cdot 15$ | (0•90-1•45) | $0 \cdot 26$ |
| Same | 138 | (33.7) | 167 | (35.5) |  |  |  |
| Better | 165 | (35.2) | 176 | (37-4) |  |  |  |
| Corneal opacity changes, baseline to 4-yr ${ }^{\text {c }}$ |  |  |  |  |  |  |  |
| Worse (More opacity) | 222 | (47-2) | 223 | (47•6) | 0.99 | (0.77-1•26) | $0 \cdot 92$ |
| Same (No change) | 184 | (39.1) | 180 | (38.5) |  |  |  |
| Better (Less opacity) | 64 | (13•6) | 65 | (13.9) |  |  |  |

${ }^{\text {a }}$ Logistic regression analysis.
${ }^{\mathrm{b}}$ Multinomial logistic regression analysis with Relative Risk Ratios (RRR).
c Ordinal logistic regression analysis.
that were associated with the outcome with $p<0.2$ into a multivariable model. Likelihood ratio test was used to decide on the covariates that should be included in the final multivariable model to determine the best fitting predictive model of risk factors for PTT at 4 years.

The trial was registered on the Pan African Clinical Trials Registry (PACTR201401000743135) and overseen by independent data and safety monitoring committee.

## 4. Role of the funding source

The funder of this long-term follow-up had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

## 5. Results

Between Feb 13, 2014, and May 31, 2014, 5168 people were examined for eligibility, of whom 4166 were ineligible and 1002 were eligible among which two ( $<1 \%$ ) declined surgery. Thus, 1000 trichiasis cases consented, were enrolled, and randomly assigned: 501 in the BLTR group and 499 in the PLTR group), Fig. 1. The 4 -year follow-up was conducted between February 1 and May

22, 2018. Among the 1000 individuals enrolled at baseline, 943 ( $94 \cdot 3 \%$ ) were re-examined: $471 / 499$ ( $94 \cdot 4 \%$ ) from the PLTR arm, and $472 / 501(94 \cdot 2 \%)$ from the BLTR arm. Reasons for loss of followup are shown in Fig. 1. About $4 \cdot 2 \%(42 / 1000)$ of the trial participants ( $2 \cdot 0 \%$ in the PLTR, and $2 \cdot 2 \%$ in the BLTR) had died during the 4 -year period.

Baseline demographic and clinical characteristics of participants seen at 4 -year were balanced between the two groups, table 1 . The mean age was 46 years and the majority were women ( $76 \cdot 2 \%$ ). Trichiasis severity and phenotypes, tarsal conjunctival inflammations, vision, and corneal opacity were comparable between the two groups. At baseline, major TT ( $>5$ lashes touching the eye) was present in similar proportions of the two arms ( $46 \%$ in PLTR, $47 \%$ in BLTR), and $76 \%$ of the trichiasis lashes were corneal in both arms. Higher proportion of cases in both arms had metaplastic only lashes ( $44 \cdot 4 \%$ in PLTR, and $41 \cdot 3 \%$ in BLTR).

At the 4 -year follow-up, PTT was observed in 169/943 (17•9\%) study eyes, among which 129 (76•3\%) had minor trichiasis (15 lashes), and 23 ( $13 \cdot 6 \%$ ) had previously received repeat surgery in the study eye between baseline and 4 -year follow-up. PTT was more frequent in the BLTR arm (105/472 [22•2\%]) than the PLTR arm ( $64 / 471[13 \cdot 6 \%]$ ), after adjusting for surgeon the OR was $1 \cdot 82$ ( $95 \%$ CI $1 \cdot 29-2 \cdot 56 ; p=0 \cdot 0006$ ). The risk difference for recurrent trichiasis between BLTR and PLTR procedures was $8 \cdot 6 \%(95 \%$ CI $3 \cdot 8-$ 13•5).


Fig. 2. Cumulative Postoperative Trachomatous Trichiasis (PTT) in 4-years by Intervention Arm.

By four years, cumulative PTT had developed in 238/996 ( $23.9 \%$ ) study eyes. PTT was more frequent in the BLTR arm (148/499 [29.7\%]) than the PLTR arm (90/497 [18•1\%]), after adjusting for surgeon the OR was $1 \cdot 91(95 \%$ CI $1 \cdot 42-2 \cdot 57 ; p<0 \cdot 0001)$, with PTT risk difference of $11 \cdot 6 \%(95 \% \mathrm{CI} 6 \cdot 3-16 \cdot 7)$. The cumulative PTT was greater in the BLTR arm than the PLTR arm at all followup time points ( 6 -month, 12 -month, and 4 -year), Fig. 2.

The secondary outcomes, all adjusted for surgeon effect, are shown in table 2 . The risk of PTT between surgeons ranged between $11 \cdot 1 \%$ and $17 \cdot 7 \%$ in the PLTR group, and $19 \cdot 2 \%$ and $28 \cdot 1 \%$ in the BLTR group. There was more under-correction in the BLTR group than the PLTR group ( $15 \cdot 6 \%$ vs $20 \cdot 8 \%$ ). Most of the undercorrection tends to be peripheral in both the PLTR ( $65 / 73$ [89•0\%]) and BLTR ( $87 / 98$ [ $88 \cdot 8 \%]$ ) surgeries. PLTR surgery had a lower risk of PTT in cases with baseline major TT than the BLTR surgery ( $17 \cdot 8 \%$ vs $31 \cdot 5 \%$ ), and performs better across all severity of entropion. Participants were also asked about their satisfaction on the surgery. Comparable proportion of participants in both treatment arms reported satisfaction with the effect of the surgery on the trichiasis ( $93 \cdot 0 \%$ PLTR and $92 \cdot 6 \%$ BLTR), and the cosmetic appearance of the operated eyelid ( $96 \cdot 2 \%$ for both surgeries). There was no evidence of a difference in logMAR visual acuity score changes ( $p=0 \cdot 26$ ), and corneal opacity grade changes ( $p=0 \cdot 92$ ) from baseline to 4 -year between the two intervention arms.

The BLTR surgery had a lower risk of ECA than the PLTR surgery ( $3 \cdot 6 \%$ vs $6 \cdot 8 \%$; RRR $0 \cdot 52$ [ $95 \% \mathrm{CI}, 0 \cdot 28-0 \cdot 95] ; p=0 \cdot 033$ ). But there was no statistically significant difference in the risk of clinically significant ECA between the two groups ( $4 \cdot 0 \%$ vs $4 \cdot 9 \%$ ), table 2. The change in ECA regression is presented in table 3. There was also no statistically significant difference in regression of ECA between the PLTR and BLTR both between 6- and 12 -months; and between 1- and 4 -years. However, among the mild ECA diagnosed at 12 -month follow-up, $81 \cdot 6 \%$ in the PLTR group, and $76 \cdot 1 \%$ in the BLTR group regressed to normal at 4 -year (sign test $p<0 \cdot 0001$ ).

Similarly, among the clinically significant ECA diagnosed at 12month, $48.3 \%$ in the PLTR group, and $51.5 \%$ in the BLTR group regressed to normal or mild ECA (sign test $p<0 \cdot 0001$ ). At 4 -year, $51 \cdot 7 \%$ and $48 \cdot 5 \%$ of cases with clinically significant ECA at 12 month remained unchanged in the PLTR and BLTR arm respectively.

There was strong evidence that major trichiasis, conjunctival scar severity, and any under correction at any location measured at immediate post-op during the baseline surgery independently predicted PTT 4-year after PLTR surgery. Increased number of peripheral dissections with scissors intraoperatively in the PLTR surgery at baseline had a long-term protective effect on postoperative TT. In the BLTR group, there was strong evidence that major trichiasis, mixed trichiasis lash location, and central under correction at immediate post-op at baseline independently predicted PTT 4-year after BLTR surgery, table 4.

Demographic and clinical factors (age, gender, trichiasis severity, entropion severity, conjunctival scarring, surgeon effect, number of scissor cuts during dissection, number of suture notes, suture knot symmetry, suture tension irregularity) that may predict ECA regression at 4 -year were analysed by intervention group and for all participants (data not provided) and there was not strong evidence found of an association of any of these with ECA regression.

## 6. Discussion

It is possible that outcomes may change a few years after TT surgery. However, the data from this long-term follow-up indicate PLTR remains superior to the BLTR with a significantly lower risk of postoperative trichiasis both cross-sectionally at and cumulatively by 4 -years after trichiasis surgery and is consistent with the oneyear results we have previously reported [9]. Moreover, PLTR still had a lower risk of PTT across all severity of trichiasis and entro-
pion groups, and had lower risk of under-correction as was found at 1 -year. These data support the WHO recommendation that new surgeons should be trained on the PLTR procedure for the programmatic management of TT [15]. We have discussed in detail in the 1 -year report why these outcome differences between the PLTR and the BLTR might have occurred [9]. We believe the PLTR procedure provides a greater, more stable outward rotation of the distal portion of the eyelid.

The major factors predicting long-term outcomes were also similar to those reported at 1-year which included preoperative disease severity and surgical factors such as peripheral dissection and under-correction [20]. Encouragingly, making adequate peripheral dissection still had a long-term protective effect on PTT in PLTR surgery indicating that it can be prevented with quality surgery and can be addressed easily during surgical trainings and supportive supervision. Special attention should also be provided for cases with advanced disease which should be operated by the most experienced surgeon available in the programme using the PLTR surgical procedure.

ECA has been a major issue for surgical programmes. It is cosmetically disfiguring, posing probably a greater concern than PTT for patients and surgeons. The good news is ECA, regressed between 6 - and 12 -months, and 1 - and 4 -years after surgery in about $73 \%$ and $66 \%$ of the cases in PLTR and BLTR surgeries respectively. However, about $50 \%$ of the clinically significant ECA cases at $12-$ month in both procedures remained un-changed. The regression seen in clinically significant ECAs between 6 and 12-month in the PLTR arm ( $15 \cdot 0 \%$ ) was much less than we have found in one of our recent trials which used the PLTR ( $40 \cdot 6 \%$ ) [10]. Rather the regression at 4 -year in this trial ( $48 \cdot 3 \%$ ) was comparable to the regression at 12 -month in the earlier trial. These results suggest that those with clinically significant disfiguring ECA need to be addressed surgically. However, in most trachoma endemic settings, neither highly skilled personnel which can correct ECA, nor a standard surgical procedure that can be used to correct ECA are available.

The strengths and limitations of this trial with regard to its design have been discussed in detail elsewhere [9,20]. We managed to follow $94 \%$ of the trial participants 4 years after enrolment. Trichiasis surgeons operated in this trial received rigorous training and standardisation. Risk of unmasking posed a potential design limitation at the 6 - and 12 -month follow-ups in relation to possibility of visible skin scar from the BLTR surgery, which was addressed with independent photographic grading. However, this was not an issue in this long-term follow-up as no eyelid skin scar would be visible 4 -years after surgery. Another potential limitation could have been unmasking of the outcome assessor as the randomisation code has been broken for earlier analyses. However, the outcome assessment was done by an independent assessor masked to allocation of intervention who had no involvement either in randomisation or data analysis.

Overall, there is strong evidence that PLTR remains superior to BLTR with reduced long-term risk of postoperative trichiasis supporting the current WHO guideline that the PLTR should be the procedure of choice for training new surgeons in the programmatic management of TT. Surgical programmes need to provide attention in improving outcomes and establish a system to comprehensively manage cases with poor surgical outcomes. The majority of PTT cases had five or less metaplastic lashes indicating that most of these cases can be treated with less invasive non-surgical methods. A relatively simple surgical procedure that can be used in trachoma endemic settings is needed to address un-resolving clinically significant ECA cases.

## Table 4

Univariable and multivariable association of factors with postoperative tt at 4 years, stratified by type of surgery.

| Demographic and Clinical Factors | PLTR ( $N=471$ )PTT |  | Univariable Analysis |  | $p$-value | Multivariable Analysis |  | BLTR ( $N=472$ ) |  |  | Univariable Analysis |  | p-value | Multivariable Analysis |  | $p$-value |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | PTT |  |  |  |  |  |  |  |  |  |  |
|  | $n / N$ | (\%) |  |  | OR | 95\% CI | OR | 95\% CI | $p$-value | $n / N$ | (\%) | OR |  | 95\% CI | OR |  | 95\% CI |
| Age, yrs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 18-29 | 6/56 | (10.7\%) | $1 \cdot 11$ | (0.93-1•34) |  | $0 \cdot 24$ | - | - | - | 7/46 | (15.2\%) | $1 \cdot 21$ | (1•04-1•41) | $0 \cdot 013$ | $1 \cdot 17$ | (1•00-1•38) | 0.054 |
| 30-39 | 7/82 | (8.5\%) |  |  |  |  |  |  | 21/106 | (19.8\%) |  |  |  |  |  |  |
| 40-49 | 18/119 | (15.1\%) |  |  |  |  |  |  | 23/105 | (21.9\%) |  |  |  |  |  |  |
| 50-59 | 16/105 | (15.2\%) |  |  |  |  |  |  | 18/98 | (18.4\%) |  |  |  |  |  |  |
| 60-69 | 13/72 | (18.1\%) |  |  |  |  |  |  | 20/78 | (25.6\%) |  |  |  |  |  |  |
| $70+$ | 4/37 | (10.8\%) |  |  |  |  |  |  | 16/39 | (41.0\%) |  |  |  |  |  |  |
| Trichiasis Severity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 25/252 | (9.9\%) | $1 \cdot 97$ | (1•15-3•37) | $0 \cdot 014$ | $2 \cdot 11$ | (1•19-3•74) | $0 \cdot 010$ | 35/250 | (14.0\%) | $2 \cdot 83$ | (1•79-4•46) | <0•0001 | $2 \cdot 30$ | (1•40-3.76) | $0 \cdot 0009$ |
| Major | 39/219 | (17•8\%) |  |  |  |  |  |  | 70/222 | (31.5\%) |  |  |  |  |  |  |
| Lash location |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Epilating | 2/38 | (5.3\%) | $0 \cdot 38$ | (0•09-1•58) | $0 \cdot 18$ | - | - | - | 9/40 | (22.5\%) | $1 \cdot 32$ | (0•60-2•91) | $0 \cdot 49$ | $1 \cdot 25$ | (0.54-2•88) | $0 \cdot 60$ |
| Corneal | 47/359 | (13.1\%) | 1 |  | - |  |  |  | 65/361 | (18.0\%) | 1 | - | - | - |  | - |
| Peripheral | 1/11 | (9•1\%) | $0 \cdot 66$ | (0.08-5•30) | $0 \cdot 70$ |  |  |  | 1/4 | (25.0\%) | $1 \cdot 52$ | (0•15-14•8) | $0 \cdot 72$ | $1 \cdot 88$ | (0•18-19•6) | $0 \cdot 60$ |
| Corneal +Peripheral | 14/63 | (22.2\%) | $1 \cdot 90$ | (0.97-3•70) | $0 \cdot 060$ |  |  |  | 30/67 | (44.8\%) | $3 \cdot 69$ | (2•12-6•41) | <0.0001 | $3 \cdot 36$ | (1•86-6•08) | $0 \cdot 0001$ |
| Tarsal conjunctiva scar |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 4/45 | (8.9\%) | $1 \cdot 81$ | (1•06-3•11) | $0 \cdot 030$ | $1 \cdot 86$ | (1•05-3•31) | $0 \cdot 034$ | 8/51 | (15.7\%) | $1 \cdot 40$ | (0.91-2•14) | $0 \cdot 12$ | - | - | - |
| Moderate | 45/358 | (12.6\%) |  |  |  |  |  |  | 77/348 | (22.1\%) |  |  |  |  |  |  |
| Severe | 15/68 | (22.1\%) |  |  |  |  |  |  | 20/73 | (27.4\%) |  |  |  |  |  |  |
| Surgeon |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 1 | 10/85 | (11.8\%) | $1 \cdot 07$ | (0•42-2•71) | $0 \cdot 40$ | - | - | - | 25/89 | (28.1\%) | $1 \cdot 64$ | (0•79-3•40) | $0 \cdot 18$ | - | - | - |
| 2 | 10/90 | (11.1\%) | 1 | - | - | - | - | - | 18/90 | (20.0\%) | $1 \cdot 05$ | (0•49-2•25) | $0 \cdot 90$ | - | - | - |
| 3 | 14/79 | (17.7\%) | $1 \cdot 72$ | (0.72-4.13) | $0 \cdot 22$ | - | - | - | 15/78 | (19.2\%) | - | - | - | - | - | - |
| 4 | 12/85 | (14.1\%) | $1 \cdot 31$ | (0.54-3.22) | $0 \cdot 55$ | - | - | - | 20/91 | (22.0\%) | $1 \cdot 18$ | (0.56-2.50) | $0 \cdot 66$ | - | - | - |
| 5 | 6/46 | (13.0\%) | $1 \cdot 20$ | (0.41-3.54) | $0 \cdot 74$ | - | - | - | 10/45 | (22.2\%) | $1 \cdot 2$ | (0.49-2•95) | $0 \cdot 69$ | - | - | - |
| 6 |  |  | $1 \cdot 30$ | (0.53-3.18) | $0 \cdot 57$ | - | - | - | 17/79 | (21.5\%) | $1 \cdot 15$ | (0.53-2.51) | $0 \cdot 72$ | - | - | - |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| No PTT | 1 | (0-26) | 0.77 | (0•63-0.95) | $0 \cdot 014$ | $0 \cdot 68$ | (0.53-0•88) | 0•0037 | 2 | (0-17) | 0.92 | (0.83-1•02) | $0 \cdot 12$ | $0 \cdot 88$ | (0.78-1•01) | 0.062 |
| PTT |  | (0-4) |  |  |  |  |  |  | 2 | (0-9) |  |  |  |  |  |  |
| Undercorrection at any part of the eyelid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| No | 53/431 | (12.3\%) | $2 \cdot 91$ | (1•36-6•20) | 0•0058 | $3 \cdot 72$ | (1•63-8•47) | 0•0018 | 96/441 | (21.8\%) | $1 \cdot 54$ | (0•68-3•47) | $0 \cdot 30$ | - | - | - |
| Yes | 11/38 | (28.9\%) |  |  |  |  |  |  | 9/30 | (30.0\%) |  |  |  |  |  |  |
| Central undercorrection |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Corrected | 54/407 | (13.3\%) | 1 | - | - | - | - | - | 90/404 | (22.3\%) | 1 | - | - | - | - | - |
| Overcorrected | 5/54 | (9.3\%) | $0 \cdot 67$ | (0.25-1•75) | $0 \cdot 41$ | - | - | - | 8/58 | (13.8\%) | $0 \cdot 56$ | (0.26-1•22) | $0 \cdot 14$ | $0 \cdot 50$ | (0.22-1•16) | $0 \cdot 10$ |
| Undercorrected | 5/10 | (50.0\%) | 6.54 | (1•83-23.3) | $0 \cdot 0038$ | - | - | - | 7/10 | (70.0\%) | $5 \cdot 70$ | (2•06-32•1) | $0 \cdot 0028$ | 8.73 | (2•02-37•7) | $0 \cdot 0037$ |




 initial model. Then tarsal conjunctival scarring was excluded from the final model after likelihood ratio test. PTT= Postoperative Trachomatous Trichiasis.

## Data sharing statement

The Amhara Regional Health Bureau Ethics Committee requires that all data sharing requests are reviewed and approved by them before data can be shared. Data is available to any researcher under reasonable request. To facilitate the data access process please contact ethics@lshtm.ac.uk.

## Funding

This four year follow-up was funded by the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD), at the Task Force for Global Health (NTD-SC 129D). The initial trial was funded by The Wellcome Trust (Grant Number 098,481/Z/12/Z).

## Declaration of Competing Interest

We declare no competing interests.

## CRediT authorship contribution statement

Esmael Habtamu: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Writing - original draft, Writing - review \& editing. Tariku Wondie: Data curation, Investigation, Project administration, Supervision, Validation, Writing review \& editing. Zerihun Tadesse: Data curation, Project administration, Supervision, Writing - review \& editing. Bezawit Atinafu: Data curation, Investigation, Project administration, Writing - review \& editing. Bizuayehu Gashaw: Data curation, Supervision, Writing - review \& editing. Abebaw Gebeyehu: Writing - review \& editing. E. Kelly Callahan: Funding acquisition, Supervision, Writing - review \& editing. David Macleod: Formal analysis, Writing review \& editing. Matthew J. Burton: Conceptualization, Funding acquisition, Methodology, Supervision, Writing - review \& editing.

## Acknowledgements

This work received financial support from the Coalition for Operational Research on Neglected Tropical Diseases, which is funded at The Task Force for Global Health primarily by the Bill \& Melinda Gates Foundation, by the United States Agency for International Development through its Neglected Tropical Diseases Program, and with UK aid from the British people. EH is supported by the Queen Elizabeth Diamond Jubilee Trust. MJB and the initial trial was funded by The Wellcome Trust (Grant Number 098481/Z/12/Z). We thank the trachoma control programme in Amhara National Regional State of Ethiopia, which is collaboration between the Regional Health Bureau and the Lions-Carter Center SightFirst Initiative; the research study team; the study participants; West Gojam Zone Health Office and the Woreda Health Offices.

## Supplementary material

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.eclinm.2019.10.015.

## References

[1] World Health Organization. Trachoma control: a guide for programme managers. Geneva, Switzerland: World Health Organization; 2006.
[2] World Health Organization. Trichiasis surgery for trachoma. Geneva, Switzerland: World Health Organization; 2013.
[3] Rajak SN, Collin JR, Burton MJ. Trachomatous trichiasis and its management in endemic countries. Surv Ophthalmol 2012;57(2):105-35.
[4] Reacher M, Huber M, Canagaratnam R, Alghassany A. A trial of surgery for trichiasis of the upper lid from trachoma. Br J Ophthalmol 1990;74(2):109-13.
[5] Reacher M, Muñoz B, Alghassany A, Daar AS, Elbualy M, Taylor HR, Muñoz B, Daar AS, Elbualy M, Taylor HR. A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch Ophthalmol 1992;110(5):667-74.
[6] Adamu Y, Alemayehu W. A randomized clinical trial of the success rates of bilamellar tarsal rotation and tarsotomy for upper eyelid trachomatous trichiasis. Ethiop Med J 2002;40(2):107.
[7] Dhaliwal U, Monga P, Gupta V. Comparison of three surgical procedures of differing complexity in the correction of trachomatous upper lid entropion: a prospective study. Orbit 2004;23(4):227-36.
[8] Nasr AM. Eyelid complications in trachoma. I. Cicatricial entropion. Ophthalmic Surg 1989;20(11):800-7.
[9] Habtamu E, Wondie T, Aweke S, Tadesse Z, Zerihun M, Zewudie Z, Kello AB, Roberts CH, Emerson PM, Bailey RL, Mabey DCW, Rajak SN, Callahan K, Weiss HA, Burton MJ. Posterior lamellar versus bilamellar tarsal rotation surgery for trachomatous trichiasis in Ethiopia: a randomised controlled trial. Lancet Global Heal 2016;4(3):e175-84.
[10] Habtamu E, Wondie T, Aweke S, Tadesse Z, Zerihun M, Gashaw B, Roberts CH, Kello AB, Mabey DCW, Rajak SN, Callahan EK, Macleod D, Weiss HA, Burton MJ. Oral doxycycline for the prevention of postoperative trachomatous trichiasis in Ethiopia: a randomised, double-blind, placebo-controlled trial. Lancet Global Heal 2018;6(5):e579-ee92.
[11] Gower EW, West SK, Harding JC, Cassard SD, Munoz BE, Othman MS, Kello AB, Merbs SL. Trachomatous trichiasis clamp vs standard bilamellar tarsal rotation instrumentation for trichiasis surgery: results of a randomized clinical trial. JAMA Ophthalmol 2013;131(3):294-301.
[12] Rajak SN, Habtamu E, Weiss HA, Kello AB, Gebre T, Genet A, Bailey RL, Mabey DC, Khaw PT, Gilbert CE. Absorbable versus silk sutures for surgical treatment of trachomatous trichiasis in Ethiopia: a randomised controlled trial. PLoS Med 2011;8(12):e1001137.
[13] Habtamu E, Burton M. Clearing the trichiasis backlog: experiences in Amhara, Ethiopia. Commun Eye Heal 2015;28(90):38.
[14] The Carter Center. Twentieth annual trachoma control program review. March 18-20, 2019; Atlanta, USA.
[15] World Health Organization Alliance for the Global Elimination of Trachoma by 2020. Second global scientific meeting on trachomatous trichiasis. South Africa: Cape Town; 4-6 November 2015.
[16] Eliminating Trachoma: Accelerating Towards 2020 WHO Alliance for the Global Elimination of Trachoma by 2020, 2016.
[17] Burton MJ, Bowman RJC, Faal H, Aryee EAN, Ikumapayi UN, Alexander NDE, Adegbola RA, West SK, Mabey DCW, Foster A, Johnson GJ, Bailey RL. Long term outcome of trichiasis surgery in the Gambia. Br J Ophthalmol 2005;89(5):575-9.
[18] Burton MJ, Kinteh F, Jallow O, Sillah A, Bah M, Faye M, Aryee EAN, Ikumapayi UN, Alexander NDE, Adegbola RA, Faal H, Mabey DCW, Foster A, Johnson GJ, Bailey RL. A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. Br J Ophthalmol 2005;89(10):1282-8.
[19] Khandekar R, Mohammed AJ, Courtright P. Recurrence of trichiasis: a long-term follow-up study in the sultanate of Oman. Ophthalmic Epidemiol 2001;8(2-3):155-61.
[20] Habtamu E, Wondie T, Aweke S, Tadesse Z, Zerihun M, Gashaw B, Wondimagegn GS, Mengistie HD, Rajak SN, Callahan K, Weiss HA, Burton MJ. Predictors of trachomatous trichiasis surgery outcome. Ophthalmology 2017;124(8):1143-55.
[21] Dawson CR, Jones BR, Tarizzo ML, World Health Organization. Guide to trachoma control in programmes for the prevention of blindness. World Health Organization; 1981. ISBN: 9241541571 p. 56.
[22] Bastawrous A, Rono HK, Livingstone IA, Weiss HA, Jordan S, Kuper H, Burton MJ. Development and validation of a smartphone-based visual acuity test (Peek acuity) for clinical practice and community-based fieldwork. JAMA Ophthalmol 2015;133(8):930-7.
[23] Gower EW, West SK, Cassard SD, Munoz BE, Harding JC, Merbs SL. Definitions and standardization of a new grading scheme for eyelid contour abnormalities after trichiasis surgery. PLoS Negl Trop Dis 2012;6(6):e1713.


[^0]:    * Corresponding author at: International Centre for Eye Health, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.

    E-mail address: esmael.al@@lshtm.ac.uk (E. Habtamu).

